$268 Billion in U.S. Life Science Investment in 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
This year, the life sciences sector has delivered.
We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $268 billion invested to drive new R&D, expand manufacturing and create jobs nationwide.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, with millions of high-skill positions for scientists and engineers, alongside tens of thousands of construction and support roles and millions of jobs for the communities surrounding these cutting edge faciltiies. This includes more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
766%
increase in facility investment announcements versus 2024
10K+
new construction jobs across America
The biopharmaceutical industry’s investments reflect a commitment to ensuring the U.S. remains a leader in the life sciences, but China continues a coordinated campaign to dominate the life sciences, jeopardizing America’s momentum.
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
Faster delivery
of breakthrough medicines to patients
U.S. Life Sciences Investment Tracker:
September 17, 2025
GSK
$30 billion
PA, NC, MD, MT
A five-year commitment to upgrade research and development and supply chain infrastructure. Includes a $1.2 billion investment in advanced U.S. manufacturing and digital capabilities, including a new biologics flex factory in Upper Merion, Pa., to produce next-generation respiratory and cancer medicines.
The investment will also bring AI and advanced digital technologies to GSK’s five existing sites in Pennsylvania, North Carolina, Maryland, and Montana, along with expanded drug substance, device, and auto-injector capabilities.
September 16, 2025
Eli Lilly
$5 billion
Goochland County-VA
The first dedicated, fully integrated API and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio. About 1,800 construction jobs and more than 650 new high-paying jobs, including engineers, scientists and lab technicians, will be brought to the Richmond, Virginia region.
Part of a larger, previously announced $27 billion company investment.
September 3, 2025
Gilead
Unspecified
Foster City-CA
A new facility that will enhance technical development and manufacturing through advanced automation, robotics, and digital monitoring. The project also expands the company’s focus on biologics.
Part of a $4 billion commitment in 2025 to U.S. capital projects.
July 21, 2025
AstraZeneca
$50 billion
MD, CA, TX, VA, IN
Pledge focus is a new drug substance manufacturing campus in Virginia and expansions of R&D and cell therapy manufacturing elsewhere.
AstraZeneca will also upgrade its U.S. clinical trial supply network and accelerate development of novel medicines.
Total investment is expected to add tens of thousands of U.S. jobs.
July 21, 2025
Biogen
$2 billion
Wake County-NC, Durham County-NC
With a manufacturing expansion and modernization in the Research Triangle, Biogen looks to enhance its capabilities for gene-targeted therapies – expanding antisense oligonucleotide production and adding new multi-platform fill-finish capacity at both clinical and commercial scales. Advanced automation and AI-driven process controls are part of the upgrades.
No entries found matching your criteria. Please modify your filters.